Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-859 Single Ascending Dose Study in Healthy Adults
NCT07736638Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ABBV-859 (8 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events up to 99 Days, Maximum Observed Serum Concentration up to 99 Days and 7 more. Started Jul 2026; status: recruiting.
02
Drugs
ABBV-859
Beyond the preview
Go deeper on NCT07736638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07736638.